162 related articles for article (PubMed ID: 37465344)
1. Pan-Cancer Analysis Reveals CENPI as a Potential Biomarker and Therapeutic Target in Adrenocortical Carcinoma.
Wu F; Li G; Shen H; Huang J; Liu Z; Zhu Y; Zhong Q; Ou R; Zhang Q; Liu S
J Inflamm Res; 2023; 16():2907-2928. PubMed ID: 37465344
[TBL] [Abstract][Full Text] [Related]
2. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract][Full Text] [Related]
3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
4. Immune infiltration related CENPI associates with the malignant features and drug resistance of lung adenocarcinoma.
Feng Z; Cui G; Tan J; Liu P; Chen Y; Jiang Z; Han Y; Zeng S; Shen H; Cai C
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167017. PubMed ID: 38232915
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value and immunological role of SULF2 in adrenocortical carcinoma.
Yan J; Xie X; Li Q; Liang P; Zhang J; Xu G
Heliyon; 2023 Feb; 9(2):e13613. PubMed ID: 36852051
[TBL] [Abstract][Full Text] [Related]
6. KIF11 is a potential prognostic biomarker and therapeutic target for adrenocortical carcinoma.
Zhou Y; Chen X; Li B; Li Y; Zhang B
Transl Androl Urol; 2023 Apr; 12(4):594-611. PubMed ID: 37181234
[TBL] [Abstract][Full Text] [Related]
7. CENPI is overexpressed in colorectal cancer and regulates cell migration and invasion.
Ding N; Li R; Shi W; He C
Gene; 2018 Oct; 674():80-86. PubMed ID: 29936263
[TBL] [Abstract][Full Text] [Related]
8. Reduced expression of ferroportin1 and ceruloplasmin predicts poor prognosis in adrenocortical carcinoma.
Zhu B; Zhi Q; Xie Q; Wu X; Gao Y; Chen X; Shi L
J Trace Elem Med Biol; 2019 Dec; 56():52-59. PubMed ID: 31442954
[TBL] [Abstract][Full Text] [Related]
9. CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle.
Huang YG; Li D; Wang L; Su XM; Tang XB
J Transl Med; 2022 Feb; 20(1):78. PubMed ID: 35123514
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive pan-cancer analysis and the regulatory mechanism of AURKA, a gene associated with prognosis of ferroptosis of adrenal cortical carcinoma in the tumor micro-environment.
Lu K; Yuan X; Zhao L; Wang B; Zhang Y
Front Genet; 2022; 13():996180. PubMed ID: 36685952
[No Abstract] [Full Text] [Related]
11. Identification of a chromatin regulator signature and potential prognostic ability for adrenocortical carcinoma.
Li J; Jia Y; Tang L; Zhang R; Zhang Y
Front Genet; 2022; 13():948353. PubMed ID: 36092868
[No Abstract] [Full Text] [Related]
12. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
13. High expression of GMNN predicts malignant progression and poor prognosis in ACC.
Zhao X; Zhang X; Shao S; Yang Q; Shen C; Yang X; Jiao W; Liu J; Wang Y
Eur J Med Res; 2022 Dec; 27(1):301. PubMed ID: 36539849
[TBL] [Abstract][Full Text] [Related]
14. An integrative analysis of enhancer of yellow 2 homolog (ENY2) as a molecular biomarker in pan-cancer.
Chen Q; Shi X; Bao Y; Sun G; Wu S; Chen Y
Funct Integr Genomics; 2023 Mar; 23(1):72. PubMed ID: 36862319
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma.
Liu J; Li W; Wu L
Front Pharmacol; 2022; 13():950156. PubMed ID: 36046831
[TBL] [Abstract][Full Text] [Related]
16. Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis.
Zhang C; Guo C; Li Y; Liu K; Zhao Q; Ouyang L
Front Cell Dev Biol; 2021; 9():726656. PubMed ID: 34409042
[TBL] [Abstract][Full Text] [Related]
17. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
18. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the E2F target gene
Thangavelu PU; Lin CY; Vaidyanathan S; Nguyen THM; Dray E; Duijf PHG
Oncotarget; 2017 Sep; 8(37):62167-62182. PubMed ID: 28977935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
